Abbott (NYSE: ABT) and BG Medicine, Inc. announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott’s ARCHITECT immunochemistry instrument platform, specifically the company’s i1000SR and i2000SR instruments. The agreement grants Abbott a [...]

Research presented at the American Association for Clinical Chemistry annual meeting shows that an assay developed by Abbott for simultaneous detection of both HIV antigens and antibodies reduced the detection window by zero to nine days in this study compared to HIV antibody-only assays. Earlier detection was shown on four of the five panels tested.